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Introduction: Recent studies have revealed that rapamycin activates autophagy in human chondrocytes preventing
the development of osteoarthritis (OA) like changes in vitro, while the systemic injection of rapamycin reduces the
severity of experimental osteoarthritis in a murine model of OA in vivo. Since the systemic use of rapamycin is
associated with numerous side effects, the goal of the current study was to examine the beneficial effect of local
intra-articular injection of rapamycin in a murine model of OA and to elucidate the mechanism of action of rapamycin
on articular cartilage.
Methods: Destabilization of the medial meniscus (DMM) was performed on 10-week-old male mice to induce OA.
Intra-articular injections of 10 μl of rapamycin (10 μM) were administered twice weekly for 8 weeks. Articular cartilage
damage was analyzed by histology using a semi-quantitative scoring system at 8 and 12 weeks after surgery.
Mammalian target of rapamycin (mTOR), light chain 3 (LC3), vascular endothelial growth factor (VEGF), collagen, type X
alpha 1 (COL10A1), and matrix metallopeptidase 13 (MMP13) expressions were analyzed by immunohistochemistry.
VEGF, COL10A1, and MMP13 expressions were further examined via quantitative RT-PCR (qPCR).
Results: Intra-articular injection of rapamycin significantly reduced the severity of articular cartilage degradation at 8
and 12 weeks after DMM surgery. A reduction in mTOR expression and the activation of LC3 (an autophagy marker) in
the chondrocytes was observed in the rapamycin treated mice. Rapamycin treatment also reduced VEGF, COL10A1,
and MMP13 expressions at 8 and 12 weeks after DMM surgery.
Conclusion: These results demonstrate that the intra-articular injection of rapamycin could reduce mTOR expression,
leading to a delay in articular cartilage degradation in our OA murine model. Our observations suggest that local
intra-articular injection of rapamycin could represent a potential therapeutic approach to prevent OA.Introduction
Osteoarthritis (OA) is the most common disorder of the
joint, causing joint pain and dysfunction in affected pa-
tients. Multiple factors have been suggested in the
pathogenesis of OA, including mechanical, genetic, and
aging-associated factors. At the cellular level, OA is
characterized by a loss of tissue cellularity and extracel-
lular matrix (ECM) damage [1]. Chondrocytes are the* Correspondence: jhuard@pitt.edu
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stated.resident cells found in cartilage tissue and are responsible
for both synthesis and turnover of the ECM [2]; therefore,
maintaining the health of chondrocytes is an important
factor for preventing articular cartilage degeneration.
Autophagy is a cellular self-digestion process which is
evolutionally observed among species and generally acti-
vated under conditions of nutrient deprivation. When
cells experience nutrient deprivation, they maintain only
the minimum amount of essential components in order
to prevent energy loss, thereby degrading unnecessary
intracellular components through the process of autoph-
agy. Thus, autophagy is perceived as an important mech-
anism for cell survival when exposed to various stresses
[3]. Recently, a growing number of studies have revealedral Ltd. This is an Open Access article distributed under the terms of the Creative
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logical housekeeping processes through the intracellular
clearance of unnecessary proteins, pathogens, and dam-
aged organelles, which include mitochondria, peroxi-
somes, and the endoplasmic reticulum (ER) [4-6]. These
functions have important implications in the pathogen-
esis of a variety of human diseases, such as neurodegen-
erative, cardiac, muscular, and inflammatory diseases [4].
One of the common pathological discoveries in such dis-
eases is the accumulation of aggregate-prone proteins,
potentially harmful to the cells, which likely occur due
to an impairment of autophagy [7]. Autophagy has,
therefore, been suggested to play a preventive role in the
development of particular human diseases. Based on the
broad cell-protective functions of autophagy, it is plausible
that autophagy play a protective role in chondrocytes
under stresses, and may prevent the OA degeneration of
chondrocytes.
Recent studies have revealed that rapamycin activates
autophagy in human chondrocytes in vitro, which acts
to prevent the expression of OA-like changes [8]. Simi-
larly, the systemic injection of rapamycin has been
shown to reduce the severity of OA in an experimental
murine model [9]. Clinically, rapamycin is currently used
as an immunosuppressant in organ transplantation pa-
tients. Clinical studies have shown that rapamycin is not
only able to provide a low rate of acute rejection and sig-
nificant improvement in kidney allograft function, but it
can also significantly decrease the incidence of post-
transplant malignancies [10,11]; however, the systemic
use of rapamycin is associated with many side effects, in-
cluding increases in serum cholesterol and triglycerides,
anemia, proteinuria, skin rashes, delayed wound healing,
and diarrhea, which can eventually lead to rapamycin
withdrawal [12].
Due to these severe side effects, the local intra-articular
injection of rapamycin may be more appropriate for clin-
ical use than systemic administration. However, it is un-
known whether the intra-articular injection of rapamycin
can affect the degeneration of articular cartilage. The ob-
jective of this study was to examine the effect of local
intra-articular injection of rapamycin on articular cartilage
in a murine model of OA. Our observations suggest that
intra-articular injection of rapamycin protects articular
cartilage from osteoarthritic changes, and may represent
an effective and safe therapeutic delivery method to pre-
vent articular cartilage degeneration.
Methods
Surgical induction of osteoarthritis in mice
All studies were performed according to protocols ap-
proved by the University of Pittsburgh’s Institutional
Animal Care and Use Committee. Forty, 10-week-old,
male C57Bl/6 J mice were used in this study. Theanimals were anesthetized with 3% isoflurane in O2 gas
(1.5 liter/minute). Experimental osteoarthritis was in-
duced by destabilizing the medial meniscus (DMM) in
the right knee [13]. Briefly, the joint capsule was opened
with an incision just medial to the patellar tendon and
the medial meniscotibial ligament was sectioned with
microsurgical scissors. As a control, surgery was per-
formed on left knee joints but the ligaments were left in-
tact and used as sham joints. All mice were allowed to
move freely within their cages after surgery. After surgical
induction of OA, the animals were divided into two
groups, namely the rapamycin treatment group and the
dimethyl sulphoxide (DMSO) (control) group. Mice were
sacrificed at 8 and 12 weeks after DMM surgery and sub-
jected to histological and gene expression analyses.
Rapamycin treatment
To perform the intra-articular injection, the animals
were first anesthetized and the skin was subsequently in-
cised longitudinally over the center of the knee joint.
The capsule and patellar tendon were exposed to clarify
the anatomy of the knee to ensure reproducible intra-
articular injection of either rapamycin or DMSO (con-
trol). Rapamycin was obtained from LC Laboratories
(Woburn, MA, USA) and was dissolved in dimethyl
sulphoxide (DMSO) to make a 50 mg/ml stock solution.
For injection, the stock solution was diluted in PBS:
10 μl of rapamycin (10 μM) with DMSO (0.02%) was
administered twice a week for 8 weeks in both knees in
the rapamycin group. The dosage and frequency of rapa-
mycin was selected based on previous studies [8,14].
These studies have demonstrated that autophagy activa-
tion by 10 μM rapamycin regulated the changes in the
expression of OA-related genes through the modulation
of apoptosis and reactive oxygen species (ROS) in
human chondrocytes in vitro [8], and the effect of rapa-
mycin on mechanical-injury-induced cell death contin-
ued up to 96 hours after treatment in ex vivo study [14].
The control group received intra-articular injections of
10 μl of DMSO (0.02%) in both knees according to the
same schedule as the rapamycin group.
Histological evaluation for articular cartilage degeneration
Six knee joints from each group were fixed in 10% neu-
tral buffered formalin, decalcified with 10% formic acid,
and embedded in paraffin. Coronal histological sections
were performed through the joint at 80-μm intervals
and stained with toluidine blue, and articular cartilage
damage was scored by two observers blinded to sample
identity using a scoring system reported by Glasson [15].
In this system, histological scores were measured in four
quadrants (medial femoral condyle, medial tibial plateau,
lateral femoral condyle, and lateral tibial plateau). The
scores are defined as follows: 0: normal; 0.5: loss of
Table 1 Primer sequences and product side for real-time
PCR
Gene 5′ DNA sequence 3′ Amplicon
length,
base pairs
VEGF Forward CCCACGTCAGAGAGCAACA 101
Reverse TCACATCTGCTGTGCTGTAGG
Col10 Forward AGGCAAGCCAGGCTATGGAA 83
Reverse GCTTCCCCGTGGCTGATATTC
MMP13 Forward GCTGCGGTTCACTTTGAGAA 106
Reverse GGCGGGGATAATCTTTGTCCA
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tions without loss of cartilage; 2: vertical clefts extending
from the articular surface down to the layer immediately
below the superficial tangential zone with some loss of
surface lamina; 3: vertical clefts/erosion extending down to
the calcified articular cartilage comprising <25% of the
quadrant width; 4: vertical clefts/erosion extending down to
the articular calcified cartilage comprising 25 to 50% of the
quadrant width; 5: vertical clefts/erosion extending down to
the calcified articular cartilage comprising 50 to 75% of the
quadrant; and 6: vertical clefts/erosion extending down to
the calcified articular cartilage comprising >75% of the
quadrant width. Ten sections of each knee joint were
scored and the final score was expressed as the summed
histologic score for each joint. The summed score repre-
sents the additive score of each quadrant of the joint on
each histologic section through the joint. This method of
analysis enabled assessment of the severity of the lesions
while also reflecting the surface area of articular cartilage
affected with OA lesions.
Immunohistochemistry
We performed immunohistochemical staining to detect
the expression of phosphor-mammalian target of rapa-
mycin (p-mTOR), light chain 3 (LC3), vascular endothe-
lial growth factor (VEGF), collagen, type X alpha 1
(COL10A1), and matrix metallopeptidase 13 (MMP13)
in the articular cartilage. Rabbit polyclonal antibodies to
p-mTOR, LC3 (Cell Signaling, Beverly, MA, USA),
VEGF, MMP13 (Abcam, Cambridge, MA, USA), and
COL10A1 (Abbiotec, San Diego, CA, USA) were used at
a 1:100 dilution and incubated overnight at 4°C. Alexa
Fluor 488-conjugated donkey anti-rabbit IgG (Molecular
Probes, Grand Island, NY, USA) was used at 1:200 dilu-
tion as the secondary antibody against the primary anti-
bodies at room temperature for 2 hours. After staining,
we evaluated the expression levels in the articular cartil-
age using Northern Eclipse software (Empix Imaging
Inc, Cheektowaga, NY, USA).
RNA isolation and quantitative RT-PCR (qPCR)
Four knee joint specimens from both the control and
experimental group were used for qPCR. Total RNA was
extracted from cartilage using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) with QIAshredder homogenizers and
the RNeasy Mini kit (Qiagen, Hilden, Germanay) according
to the manufacturer’s protocol. One microgram of total
RNA was used for random hexamer-primed cDNA synthe-
sis using the SuperScript II pre-amplification system
(Invitrogen, Carlsbad, CA,USA). Quantitative RT-PCR
reactions were performed in triplicate using iQ5 (Bio-Rad,
Hercules, CA, USA) with Maxima SYBR Green/ROX qPCR
Master Mix (Thermo, Thermo Scientific, Rockford, IL,
USA) and 300 nM of each primer. The primers weredesigned based on the sequences in the GenBank database.
The primer pairs used for this study are shown in Table 1.
Specificity of the reactions was confirmed by 2.5% agarose
gel electrophoresis.
Statistical analysis
All the data were expressed as the mean ± SD. The Mann-
Whitney U-test was used for direct comparisons between
the two groups. One-way analysis of variance (ANOVA)
or the Kruskal-Wallis test was applied for multiple com-
parisons between independent groups. Pairwise, multiple
comparisons were performed using the Tukey-Kramer or
Scheffé post hoc test. Data analyses were performed using
PASW Statistics 21 (SPSS, Chicago, IL, USA). Statistical
significance was determined at level of P <0.05.
Results
The local intra-articular injection of rapamycin delayed
articular cartilage degradation
There were no structural changes at the anterior cruciate
ligament or meniscus identified in the sham knees that
were treated with rapamycin or DMSO. Side effects such
as weight loss, skin rashes, delayed wound healing, or diar-
rhea were not observed after local intra-articular injection
of rapamycin. Histological sections demonstrated signifi-
cantly less articular cartilage degeneration in the experi-
mental group treated with local intra-articular injections
of rapamycin at 8 and 12 weeks after induction of OA
with DMM surgery compared to the OA-induced mice
treated with DMSO. Histological grading showed that the
DMSO-treated mice had a loss of proteoglycan staining
with articular fibrillation at 8 weeks and losses of hyaline
cartilage, proteoglycan staining, and lesions extending into
the calcified cartilage at 12 weeks after surgery (Figure 1A).
In contrast, rapamycin-treated mice showed a focal loss of
proteoglycan staining without severe articular cartilage
loss at 8 weeks and lesions with a loss of proteoglycan
staining slightly increased 12 weeks after surgery; however,
hyaline cartilage was preserved (Figure 1B). The extent of
OA was evaluated by scoring specific parameters of OA,
and is presented as summed scores (the higher the score
Figure 1 Histological evaluation of osteoarthritis (OA). (A, B) Representative images of toluidine blue staining from dimethyl sulphoxide
(DMSO) (A) and rapamycin (B) treated mice at 8 and 12 weeks after destabilization of the medial meniscus (DMM) or sham surgery. Boxed areas
in the toluidine blue stained image at the left side (x4) indicate the regions shown in the enlarged toluidine blue stained area at the right side
(x20). Scale bar = 500 μm (x4) and 100 μm (x10). Arrows indicate the osteoarthritic change after DMM surgery. (C) Graph indicating the summed
OA scores. Summed OA scores were calculated from all four quadrants and eight sections from each knee. ***P <0.001, **P <0.01.
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Table 2). Using the summed OA score, DMSO-treated
mice developed OA in a time-dependent manner and
had a significantly higher score than the rapamycin-
treated mice at 8 and 12 weeks following DMM surgery
(Figure 1C, P = 0.001 at 8 weeks and P <0.001 at
12 weeks). The summed OA score in the rapamycin-
treated mice at 12 weeks was increased compared to the
score at 8 weeks (Figure 1C, P <0.001). These results sug-
gested that the intra-articular injection of rapamycin didTable 2 Summed score
Summed score
Sham 8 weeks DMSO 9.7 (SD 2.9)
Rapamycin 10.2 (SD 2.5)
DMM 8 weeks DMSO 34.7 (SD 4.5)
Rapamycin 20.5 (SD 3.6)
DMM 12 weeks DMSO 52.2 (SD 6.0)
Rapamycin 33.3 (SD 3.3)
DMM, destabilization of the medial meniscus; DMSO, dimethyl sulphoxide.not completely prevent, but delayed articular cartilage
degradation in the presence of meniscus injury after
DMM surgery.
The local intra-articular injection of rapamycin decreased
p-mTOR and increased LC3 expression
To determine whether the local intra-articular injection
of rapamycin modulates mTOR and autophagy, the ef-
fects that rapamycin had on phospho-mTOR (p-mTOR)
and LC3 expressions were examined. The expression of
p-mTOR was increased in DMSO-treated mice at 8 and
12 weeks post DMM surgery compared to DMSO-
treated mice undergoing the sham knee operation. Rapa-
mycin treatment suppressed p-mTOR expression in
these mice compared to those treated with DMSO at
both the 8- and 12-week time points post DMM injury.
The expression of p-mTOR in the rapamycin-treated
mice was significantly increased at 12 weeks compared
to 8 weeks after DMM injury (at 8 weeks DMSO 108.5 ±
13.3, rapamycin 43.0 ± 8.9; at 12 weeks DMSO 273.8 ±
27.0, rapamycin 76.5 ± 14.7) (Figure 2A, B). In contrast,
Figure 2 The effect of rapamycin on phospho- mammalian target of rapamycin (p-mTOR) and light chain 3 (LC3) expression.
(A) Representative images of immunostaining for p-mTOR (green) and LC3 (green). Scale bar = 20 μm. (B) Quantification of p-mTOR-positive cells was
calculated. Rapamycin treatment suppressed p-mTOR expression in the rapamycin-treated mice compared to those treated with dimethyl sulphoxid
(DMSO) at both the 8- and 12-week time points (at 8 weeks DMSO 108.5 ± 13.3, rapamycin 43.0 ± 8.9 mm; at 12 weeks DMSO 273.8 ± 27.0, rapamycin
76.5 ± 14.7 mm). (C) Quantification of LC3-positive cells was calculated. **P <0.01, ***P <0.001. DMM, destabilization of the medial meniscus.
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age maintaining proteoglycan staining but fewer in the
degenerated articular cartilage of the DMSO-treated mice
after DMM surgery. An increase in LC3-positive cells was
observed in the rapamycin-treated mice compared to those
treated with DMSO at 8 and 12 weeks post DMM surgery.
The number of LC3-positive cells in the rapamycin-treated
mice decreased significantly at 12 weeks compared to
8 weeks post DMM injury (at 8 weeks DMSO 88.2 ± 13.1,
rapamycin 236.0 ± 56.3; at 12 weeks DMSO 46.2 ± 12.8,
rapamycin 106.3 ± 27.1) (Figure 2A, C).
The intra-articular injection of rapamycin decreased VEGF
expression in articular cartilage
As it has been reported that the expression of VEGF is
related to the development of OA changes [16], VEGF
expression was examined with immunohistochemistry
and qPCR (Figure 3). The number of VEGF-positive
cells in the articular cartilage was significantly lower in
the rapamycin group compared with the DMSO group
at 8 and 12 week post DMM injury (at 8 weeks DMSO
143.8 ± 29.6, rapamycin 21.2 ± 8.4, P <0.001 for DMSO
versus rapamcyin; at 12 weeks DMSO 275.5 ± 56.9,rapamycin 96.0 ± 27.8, P <0.001 for DMSO versus rapam-
cyin). The number of VEGF-positive cells in the rapamycin-
treated mice increased at 12 weeks compared to 8 weeks
post DMM injury (P <0.001 for DMSO at 8 weeks versus
12 weeks) (Figure 3A, B). Similarly, the expression of VEGF
by qPCR revealed a significant increase in the DMSO-
treated mice at 8 weeks after DMM surgery compared to
sham knees (Figure 3C, P <0.001 relative to sham). Rapa-
mycin treatment decreased VEGF expression when com-
pared to the DMSO-treated mice at the 8 and 12 week time
points post DMM injury (Figure 3C, P <0.001 at 8 and
12 weeks), suggesting that the local intra-articular injection
of rapamycin reduced articular cartilage damage, at least in
part, through a reduction in VEGF expression.
The local intra-articular injection of rapamycin decreased
CoL10A1 and MMP13 expression
To investigate the mechanism behind rapamycin’s ability
to prevent experimental OA, subsequent experimen-
tation focused on chondrocyte hypertrophy and con-
sequently the expression of COL10A1 and MMP13
(hypertrophic chondrocyte markers) was examined by im-
munohistochemistry and qPCR (Figures 4, 5). The number
Figure 3 The effect of rapamycin on vascular endothelial growth factor (VEGF) expression in the articular cartilage. (A) Representative
images of immunostaining for VEGF (green). Scale bar = 20 μm. (B) Quantification of VEGF-positive cells in the cartilage was calculated. (C) Graph
indicating quantitative RT-PCR for VEGF in dimethyl sulphoxide (DMSO)- and rapamycin-treated mice at 8 and 12 weeks after destabilization of
the medial meniscus (DMM) or sham surgery. *P <0.05, **P <0.01, ***P <0.001.
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nificantly lower in the rapamycin group when compared
to the DMSO group at 8 and 12 weeks post DMM injury
(at 8 weeks DMSO 88.2 ± 13.1, rapamycin 236.0 ± 56.3,
P <0.001 for DMSO versus rapamcyin; at 12 weeks
DMSO 46.2 ± 12.8, rapamycin 106.3 ± 27.1, P <0.001 for
DMSO versus rapamcyin). The number of CoL10A1-
positive cells in the rapamycin-treated mice increased atFigure 4 The effect of rapamycin on collagen, type X alpha 1 (COL10
immunostaining for COL10A1 (green). Scale bar = 20 μm. (B) Quantification
indicating quantitative RT-PCR for COL10A1 in dimethyl sulphoxide (DMSO
the medial meniscus (DMM) injury. ***P <0.001, **P <0.01.12 weeks compared to 8 weeks post DMM injury (P <0.001
for DMSO at 8 weeks versus 12 weeks) (Figure 4A, B).
Similarly the expression of COL10A1, as measured by
qPCR, was increased in the DMSO-treated mice at 8 and
12 weeks after DMM surgery compared to the sham knees
(Figure 4C: P = 0.006 at 8 weeks, P <0.001 at 12 weeks,
respectively). Also intra-articular injection of rapamycin sig-
nificantly decreased the expression of COL10A1 comparedA1) expression in articular cartilage. (A) Representative images of
of COL10A1-positive cells in the cartilage was calculated. (C) Graph
)- and rapamycin-treated mice 8 and 12 weeks after destabilization of
Figure 5 The effect of rapamycin on matrix metallopeptidase 13 (MMP13) expression in articular cartilage. (A) Representative images of
immunostaining for MMP13 (green). Scale bar = 20 μm. (B) Quantification of MMP13-positive cells in the cartilage was calculated. (C) Graph
indicating quantitative RT-PCR for MMP13 in dimethyl sulphoxide (DMSO)- and rapamycin-treated mice 8 and 12 weeks after destabilization of
the medial meniscus (DMM) injury. ***P <0.001, **P <0.01.
Takayama et al. Arthritis Research & Therapy 2014, 16:482 Page 7 of 10
http://arthritis-research.com/content/16/6/482to the DMSO-treated mice at 8 and 12 weeks after DMM
surgery (Figure 4C: P = 0.001at 8 weeks, P <0.001 at
12 weeks, respectively).
The number of MMP13-positive cells in the cartilage
was significantly lower in the rapamycin group com-
pared with the DMSO group at 8 and 12 weeks post
DMM injury (at 8 weeks DMSO 198.2 ± 34.6, rapamycin
18.0 ± 5.7, P <0.001 for DMSO versus rapamcyin; at
12 weeks DMSO 249.8 ± 31.1, rapamycin 77.8 ± 10.0,
P <0.001 for DMSO versus rapamcyin). The number
of MMP13-positive cells in the rapamycin-treated mice in-
creased at 12 weeks compared to 8 weeks post DMM in-
jury (P <0.01 for DMSO at 8 weeks versus 12 weeks)
(Figure 5A, B). Rapamycin treatment reduced MMP13 ex-
pression, as measured by qPCR, at 8 and 12 weeks after
DMM surgery compared to the MMP13 expression in the
DMSO-treated mice (Figure 5C, P = 0.026 at 8 weeks,
P <0.001 at 12 weeks). These results suggest that mTOR
inhibition with rapamycin decreases hypertrophic change
in articular cartilage after DMM surgery.
Discussion
The results of the current study are the first to demon-
strate that articular cartilage degeneration occurring
after DMM surgery correlates with increased in mTOR
expression, and consequently local intra-articular injec-
tion of rapamycin reduced mTOR expression, which de-
layed articular cartilage degradation. Recently, systemic
injection of rapamycin has been shown to reduce the se-
verity of OA in an experimental murine model [9]. The
systemic use of rapamycin in the clinical setting isassociated with many side effects, such as weight loss,
skin rashes, delayed wound healing, or diarrhea, which
can eventually lead to rapamycin withdrawal [12]. In this
study, these side effects were not observed after local
intra-articular injection of rapamycin. The local intra-
articular injection of rapamycin might be more appropri-
ate for clinical use than systemic administration.
In this study, we demonstrated that after surgically in-
ducing joint instability, chondrocytes in the articular car-
tilage displayed increased mTOR expression during the
progression of OA, suggesting that the activation of
mTOR leads to articular cartilage degeneration. Further-
more, the inhibition of mTOR with rapamycin promoted
a significant delay in the progression of OA changes, as
demonstrated histologically by staining the AC for pro-
teoglycan content.
Recent studies have demonstrated that mTOR inhib-
ition by rapamycin triggers a negative feedback loop,
resulting in the activation of Akt signaling [17,18]. In
adult articular cartilage, phosphoinositide 3 (PI-3)
kinase-Akt signaling promotes matrix synthesis as well
as the survival of chondrocytes. Activation of Akt in hu-
man articular chondrocytes significantly increase proteo-
glycan synthesis and type II collagen expression [19-21]
(Figure 6). Another important function of the mTOR
signaling pathway is the regulation of autophagy, a
process in which the cell degrades damaged or excess
cellular components, ranging from individual proteins
and protein aggregates to whole organelles, through the
use of the cell lysosomal machinery. A previous in vitro
study indicated that autophagy activation by 10 μM
Figure 6 Proposed schematic model showing how rapamycin modulates osteoarthritis (OA) in our animal model. There are three
potential mechanisms by which rapamycin has a beneficial effect on OA (autophagy, vascular endothelial growth factor (VEGF), and the Akt
pathway). mTOR, mammalian target of rapamycin; MMP13, matrix metallopeptidase 13; COL10A1, collagen, type X alpha 1.
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related genes through the modulation of apoptosis and
reactive oxygen species (ROS) in human chondrocytes
[8]. Similarly, during the development of OA, autophagy
increased as an adaptive response to protect the cells
from various stresses, while in severely damaged articu-
lar cartilage, autophagy was reduced [8]. The present
study demonstrated that LC3-positive cells resided in
healthy articular cartilage maintaining proteoglycan stain-
ing, and LC3-expressing cells decreased in degenerating
articular cartilage after DMM surgery. Thus, it is plausible
that articular cartilage degradation after surgical induction
of OA is partially due to insufficient autophagy. In support
of this hypothesis, our results also indicate that the benefi-
cial effect of local intra-articular rapamycin treatment on
OA-induced cartilage damage correlates with an increase
in LC3-expressing cells (Figure 6).
Subsequently, we focused on the potential role of
angiogenesis in modulating articular cartilage degener-
ation after OA and whether the beneficial effect of rapa-
mycin can be explained by modulation of angiogenesis.
Accumulating evidence indicates that joints affected by
OA contain increased levels of VEGF in their articular
cartilage and synovial fluid as well as several cytokines
that stimulate VEGF production [16,22,23]. In a recent
publication we have demonstrated that the intra-articular
injection of stem cells transduced with sFLT1, an antagon-
ist of VEGF, could reduce angiogenesis and improve the
regeneration of articular cartilage without osteophyte de-
velopment in a rat model of OA [24]. Interestingly, mTOR
activation stimulates VEGF [25,26], whereas rapamycin
treatment reduces VEGF expression, which leads to the
suppression of endothelial cell proliferation, survival, and
migration [27]. In the current study, local intra-articular
injection of rapamycin decreased the expression of VEGFafter DMM when compared with the DMSO-treated mice,
suggesting that decreased VEGF expression might play a
role in the beneficial effect of rapamycin on articular car-
tilage after OA (Figure 6).
To further examine the beneficial effect of rapamycin on
articular cartilage after OA, we investigated chondrocyte
hypertrophy. Chondrocyte hypertrophic-like changes also
contribute to the progression of early and late stages of
OA [28]. The induction of hypertrophic-like changes in
healthy human chondrocytes causes calcification of the
extracellular matrix [29,30]. Recently, hypertrophic dif-
ferentiation of chondrocytes has also been reported to
promote angiogenesis [31]; hence, the inhibition of chon-
drocyte hypertrophic-like alterations could be a thera-
peutic target to block the progression of OA [28]. mTOR
is associated with the development of hypertrophic
changes [32-34], and mTOR inhibition by rapamycin de-
creases chondrocyte hypertrophy in the growth plate
[35,36]. The expression of COL10A1 and MMP13 are the
most widely used markers for identifying hypertrophic
chondrocytes [37-39]. In the current study, rapamycin
treatment was found to reduce the expression of COL10A1
and MMP13 in comparison to mice treated with DMSO
after DMM surgery. However, in the rapamycin-treated
mice, the expression of COL10A1 and MMP13 at 12 weeks
were increased compared to those at 8 weeks. These find-
ings suggest that the intra-articular injection of rapamycin
reduced the hypertrophic changes in the articular cartilage
in this experimental model of OA, which contributed to a
delay in OA progression.
There are some limitations in this study. First, the op-
timal dosage and frequency of rapamycin might be dif-
ferent in mice and humans, although the results suggest
that local intra-articular injection of rapamycin delayed
articular cartilage degradation. We also need to examine
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lower dosage and frequency in larger animal models, be-
fore we apply the injection of rapamycin in a clinical set-
ting. Second, experimental OA was induced by DMM.
Lesions in the DMM model progressed from mild to
moderate OA compared to the anterior cruciate liga-
ment transection model. Therefore, experimental OA in-
duced by DMM differs from the primary OA observed
in humans. In addition, young mice were used in this
study, and although young mice have been widely used
for this type of study, the regenerative capacity in young
animals is most likely superior to that of aged animals,
which could obscure the process of cartilage degener-
ation. In future studies, aged and large animal models
should be utilized to test the effects of rapamycin treat-
ment on articular cartilage in primary OA.Conclusion
In conclusion, our results demonstrated that the intra-
articular injection of rapamycin reduce mTOR expres-
sion, which leads to a delay in cartilage degradation after
surgically inducing joint instability. Activation of LC3
(an autophagy marker) in the OA-induced chondrocytes
as well as reduction in VEGF, COL10A1, and MMP13
expression was also observed in the rapamycin-treated
knees. Our observations suggest that local intra-articular
injection of rapamycin may represent a strategy to pre-
vent the development of articular cartilage damage,
while limiting the side effect of systemic delivery of
rapamycin. Further studies that explore mTOR inhib-
ition will provide novel insights into the pathophysi-
ology of OA and could lead to the establishment of
new therapeutic approaches for slowing the progression
of OA.
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